The dawn of precision medicine in diffuse-type gastric cancer

por Ooki, Akira, Yamaguchi, Kensei
Publicado 2022

Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer

por Osumi, Hiroki, Shinozaki, Eiji, Yamaguchi, Kensei
Publicado 2020

Immunotherapy in Colorectal Cancer: Current and Future Strategies

por Ooki, Akira, Shinozaki, Eiji, Yamaguchi, Kensei
Publicado 2021

Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era

por Shimozaki, Keitaro, Nakayama, Izuma, Hirota, Toru, Yamaguchi, Kensei
Publicado 2023

Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma

por Ooki, Akira, Osumi, Hiroki, Fukuda, Koshiro, Yamaguchi, Kensei
Publicado 2023

Germline Mutation of Dihydropyrimidine Dehydrogenese Gene among a Japanese Population in Relation to Toxicity to 5‐Fluorouracil

por Yamaguchi, Kensei, Aral, Yoshiko, Kanda, Yuzo, Akagi, Kiwamu
Publicado 2001

Clinical utility of circulating tumor DNA for colorectal cancer

por Osumi, Hiroki, Shinozaki, Eiji, Yamaguchi, Kensei, Zembutsu, Hitoshi
Publicado 2019

Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer

por Osumi, Hiroki, Shinozaki, Eiji, Yamaguchi, Kensei, Zembutsu, Hitoshi
Publicado 2019

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

por Ooki, Akira, Osumi, Hiroki, Chin, Keisho, Watanabe, Masayuki, Yamaguchi, Kensei
Publicado 2023

Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation

por Udagawa, Shohei, Ooki, Akira, Shinozaki, Eiji, Fukuda, Koshiro, Yamaguchi, Kensei, Osumi, Hiroki
Publicado 2023

Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer

por Shitara, Kohei, Baba, Eishi, Fujitani, Kazumasa, Oki, Eiji, Fujii, Satoshi, Yamaguchi, Kensei
Publicado 2021

A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan

por Chen, Yucherng, Katayose, Taeko, Nagaoka, Soshi, Piao, Yongzhe, Yamaguchi, Kensei, Asou, Hiroya
Publicado 2021

Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study

por Sakata, Hidenori, Murase, Maki, Kato, Takeshi, Yamaguchi, Kensei, Sugihara, Kenichi, Suzuki, Shigenobu, Yoshino, Takayuki
Publicado 2022

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer

por Cremolini, Chiara, Montagut, Clara, Ronga, Philippe, Venturini, Filippo, Yamaguchi, Kensei, Stintzing, Sebastian, Sobrero, Alberto
Publicado 2023

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer

por Ishiguro, Megumi, Watanabe, Toshiaki, Yamaguchi, Kensei, Satoh, Taroh, Ito, Hideyuki, Seriu, Taku, Sakata, Yuh, Sugihara, Kenichi
Publicado 2012

Severe Infusion Reactions to Cetuximab Occur within 1 h in Patients with Metastatic Colorectal Cancer: Results of a Nationwide, Multicenter, Prospective Registry Study of 2126 Pati...

por Yamaguchi, Kensei, Watanabe, Toshiaki, Satoh, Taroh, Ishiguro, Megumi, Izawa, Makiko, Inoshiri, Shogo, Sugihara, Kenichi, Sakata, Yuh
Publicado 2014

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after che...

por Yamaguchi, Kensei, Boku, Narikazu, Muro, Kei, Yoshida, Kazuhiro, Baba, Hideo, Tanaka, Shinji, Akamatsu, Ayumi, Sano, Takeshi
Publicado 2021

Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases

por Ichida, Hirofumi, Mise, Yoshihiro, Ito, Hiromichi, Ishizawa, Takeaki, Inoue, Yosuke, Takahashi, Yu, Shinozaki, Eiji, Yamaguchi, Kensei, Saiura, Akio
Publicado 2019

In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells

por Mashima, Tetsuo, Iwasaki, Risa, Kawata, Naomi, Kawakami, Ryuhei, Kumagai, Koshi, Migita, Toshiro, Sano, Takeshi, Yamaguchi, Kensei, Seimiya, Hiroyuki
Publicado 2019

ALDH1A3‐mTOR axis as a therapeutic target for anticancer drug‐tolerant persister cells in gastric cancer

por Kawakami, Ryuhei, Mashima, Tetsuo, Kawata, Naomi, Kumagai, Koshi, Migita, Toshiro, Sano, Takeshi, Mizunuma, Nobuyuki, Yamaguchi, Kensei, Seimiya, Hiroyuki
Publicado 2020